Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Xeris Pharmaceuticals

Xeris Pharmaceuticals

Xeris Pharmaceuticals is a pharmaceutical company developing liquid-stable injectables founded in 2005 by John Kinzell.

Xeris Pharmaceuticals, Inc. is a pharmaceutical company. It is a company that engages in developing and commercializing injectable and infusible drug formulations. The company uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.

The company's formulation technologies enable the subcutaneous and intramuscular delivery of formulations of peptides, proteins, antibodies and small molecules using commercially available syringes, multi-dose pens, auto-injectors, and infusion pumps.

Xeris is developing its lead product candidate, the Glucagon Rescue Pen, for the purpose of treating severe hypoglycemia in people with diabetes. It is also involved in the development of treatments for post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure and exercise-induced hypoglycemia. Its Glucagon Rescue Pen provides a stable glucagon that is designed to be administered subcutaneously in a simple two-step process.

Timeline

December 12, 2011
Xeris Pharmaceuticals raises a $1,500,000 series A round.

Funding Rounds

Acquisitions

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Halper Sadeh LLP
June 1, 2021
www.prnewswire.com:443
/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Talend S.A. (NASDAQ: TLND)...
Monteverde & Associates PC
May 29, 2021
www.prnewswire.com:443
/PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS...
WeissLaw LLP
May 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Strongbridge...
Xeris Pharmaceuticals, Inc.
May 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and...
Pomerantz LLP
March 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Xeris Pharmaceuticals, Inc. ("Xeris" or the "Company") (NASDAQ: XERS). Such...
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.